Skip to main content

ProductLife Group (PLG) Acquires Callisto to Strengthen Regulatory Services in the UK and EU

Written by Customer Service on . Posted in Mergers And Acquisitions.

PARIS, Oct. 30, 2024 (GLOBE NEWSWIRE) — ProductLife Group (PLG), a global leader in regulatory, scientific, compliance, and digital transformation consulting services for the life sciences industry, is excited to announce the acquisition of Callisto, a leading UK-based consultancy specializing in Regulatory Affairs (RA), Pharmacovigilance (PV) and GMDP services within multiple regulated sectors including human and veterinary medicines, medical devices, and borderline products.

Founded in 2003, Callisto has a strategic geographical presence in both the UK and Ireland and serves more than a hundred clients, with over 85% repeat business, demonstrating their commitment to delivering exceptional client service.

Originally serving clients from its UK base, Callisto expanded operations in 2018 by opening an affiliate in Dublin, to ensure seamless EU regulatory, GMP and pharmacovigilance services following Brexit.

This acquisition further enhances PLG’s presence in the UK, following the recent acquisition of Integrity. With 37 people and offices in Lockington, Derbyshire (England) and Dublin (Ireland), Callisto’s services perfectly align with PLG’s core business areas, allowing for significant synergies and growth opportunities. The combined capabilities of PLG and Callisto enable end-to-end regulatory solutions designed to streamline development, market entry, and compliance strategies across global markets.

Callisto’s Managing Director and one of the original founders, Joanne Bunyan, commented: “This partnership marks a new important milestone in our growth journey. As Callisto integrates with PLG, we are forging a powerful alliance in the regulatory arena, bringing our regulatory, GMP and compliance expertise to a broader audience, while still delivering high-quality service to our clients in the UK and Europe.”

Xavier Duburcq, CEO of PLG, added: “PLG and Callisto joining forces offers great potential to our complementary client bases and will contribute to the successful development of our operations and business in the UK. Our positive cultures and values are very well-matched and expanding PLG in this region with the similarly motivated team at Callisto should bring exciting opportunities for all.”

About ProductLife Group:

ProductLife Group’s mission is to support patient access to safe and effective healthcare solutions by delivering worldwide consulting and outsourcing services through the entire product life. Combining local expertise with global reach spanning more than 150 countries, PLG is the Life Sciences Industry reference strategic partner for the development, market introduction and life cycle management of product portfolios, and the related business and digital transformation. With a goal of continuously improving the value delivered to teams and clients, PLG is committed to long-term partnership, innovation, flexibility, and cost efficiency.

For more information, visit https://productlifegroup.com/
Contact:
Fabrice Galzin
ProductLife Group Head of Marketing
fgalzin@productlife-group.com

About Callisto

Founded in 2003 as Callisto Regulatory Consulting Ltd, Callisto Pharma Group has evolved into a comprehensive consultancy providing a full range of technical services across the entire supply chain within multiple regulated sectors, including human, veterinary and herbal medicines, borderline products, biocides, medical devices, and food supplements.
Callisto works with clients across the UK, Europe and globally, supporting businesses in highly regulated industries—from global multi-nationals to single product licence holders. The group offers product release and QP technical support to manufacturers and licence holders, holding MIA’s and ManA/VIA granted by both the MHRA and HPRA, allowing them to assist clients in importing licensed and unlicenced human and veterinary products into the UK and Europe.

For more information, visit https://www.callistopharmagroup.com/
Contact:
Paul Bunyan
Operations Director
paul@callistopharmagroup.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.